Endo Pharmaceuticals to Announce Second Quarter 2009 Financial Results on July 30, 2009
Posted on: Wednesday, 1 July 2009, 15:52 CDT
Investors and other interested parties may call 800-901-5248 (domestic) or 617-786-4512 (international) and enter passcode 39225165. Please dial in 10 minutes prior to the scheduled start time.
A replay of the call will be available from
A simultaneous webcast of the call may be accessed by visiting www.endo.com. In addition, a replay of the webcast will be available until
About Endo
Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, overactive bladder, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP). Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and VOLTAREN(R) Gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment such as those of the hands and the knees. Voltaren(R) Gel is owned and licensed by Novartis AG; SANCTURA(R) and its XR version for treatment of overactive bladder, VANTAS(R) for the palliative treatment of advanced prostate cancer, and SUPPRELIN(R) LA for the treatment of early onset puberty in children. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, endocrinology and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.
SOURCE Endo Pharmaceuticals
Source: PR Newswire
Related Articles
- Labopharm Announces FDA Approval of Once-Daily RYZOLT(TM) (Tramadol HCL Extended Release Tablets) for Management of Moderate to Moderately Severe Chronic Pain
- Pain Therapeutics and King Pharmaceuticals Develop a New Abuse-Resistant Prescription Pain Medication
- Biovail Receives Canadian Approval for Ralivia(TM) for the Treatment of Moderately Severe Pain
- Repros Therapeutics Inc. Announces That Proellex Significantly Reduces Pain in a U.S. Phase 2 Clinical Trial in Women With Moderate to Severe Endometriosis
- Toshiba Net Phone 6.0 Delivers Powerful Presence Capabilities for Call Center and General Office Use
- Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
- FDA Approves Oscient Pharmaceuticals' FACTIVE(R) Tablets for Five-Day Treatment of Community-Acquired Pneumonia
- New, Once Daily Medicine Available for Treatment for Moderate to Moderately Severe Chronic Pain in Adults
- Oscient Pharmaceuticals' FACTIVE Tablets Subject of Poster Presentations at European Congress of Clinical Microbiology and Infectious Diseases; Leading European Conference Draws Key Scientific and Pharmaceutical Decision Makers
- Rivastigmine and Donepezil Treatment in Moderate to Moderately- Severe Alzheimer's Disease Over a 2-Year Period
 |
 |
User Comments (0)
RSS Feeds